Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Roche Holdings Ltd ADR (RHHBY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 214,685,728
  • Shares Outstanding, K 6,815,420
  • Annual Sales, $ 56,655 M
  • Annual Income, $ 8,774 M
  • 36-Month Beta 0.54
  • Price/Sales 3.99
  • Price/Cash Flow 12.55
  • Price/Book 7.12
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 07/26/18
  • Annual Dividend & Yield 0.89 (2.82%)
  • Most Recent Dividend 0.918 on 03/15/18
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
30.4900 +3.41%
on 11/15/18
32.5800 -3.22%
on 12/03/18
+0.2350 (+0.75%)
since 11/09/18
3-Month
28.7400 +9.71%
on 10/25/18
32.5800 -3.22%
on 12/03/18
+0.8400 (+2.74%)
since 09/10/18
52-Week
26.3000 +19.89%
on 06/08/18
32.5800 -3.22%
on 12/03/18
+1.3100 (+4.33%)
since 12/08/17

Most Recent Stories

More News
Roche's Tecentriq Gets FDA Approval for First-Line NSCLC

Roche's (RHHBY) Tecentriq in combination with Avastin obtains FDA nod for the initial treatment of NSCLC.

MRK : 77.42 (+0.91%)
GILD : 67.49 (-0.97%)
RHHBY : 31.5300 (+0.10%)
BMY : 52.58 (-0.94%)
Amgen (AMGN) Continues to Reward Shareholders, Ups Dividend

Amgen (AMGN) hikes its quarterly dividend by 10%.

NVS : 86.90 (-0.21%)
ABBV : 87.61 (+0.75%)
RHHBY : 31.5300 (+0.10%)
AMGN : 194.09 (+1.38%)
FDA Approves Genentech's Tecentriq in Combination With Avastin and Chemotherapy for the Initial Treatment of People With a Specific Type of Metastatic Lung Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq(R) (atezolizumab), in combination...

RHHBY : 31.5300 (+0.10%)
Roche's Kadcyla Halves Death Risk in Breast Cancer Study

Roche (RHHBY) announces detailed data from a late-stage study on Kadcyla in early breast cancer patients. Kadcyla reduces risk of disease recurrence by 50% compared to Herceptin.

IMGN : 5.38 (+0.75%)
NVS : 86.90 (-0.21%)
TEVA : 18.44 (-5.00%)
RHHBY : 31.5300 (+0.10%)
AbbVie Halts Rova-T Phase III Second-Line Lung Cancer Study

IDMC recommends AbbVie (ABBV) to stop enrolment in a late-stage study on its small cell lung cancer candidate, Rova-T.

MRK : 77.42 (+0.91%)
JNJ : 145.26 (-0.12%)
ABBV : 87.61 (+0.75%)
RHHBY : 31.5300 (+0.10%)
Exelixis Initiates Pivotal Liver Cancer Study on Cabometyx

Exelixis (EXEL) and its partner announce initiation of a pivotal study to evaluate its kidney cancer drug, Cabometyx, in combination with Roche's Tecentriq in liver cancer.

BAYRY : 17.5150 (-3.21%)
EXEL : 21.36 (+3.99%)
RHHBY : 31.5300 (+0.10%)
PFE : 44.40 (+1.09%)
J&J's Blood Cancer Drugs Succeed in Label Expansion Studies

J&J (JNJ) presents positive data from late-stage studies evaluating its blood cancer drugs, Imbruvica and Darzalex, in the first-line setting at ASH.

CELG : 68.68 (-2.00%)
JNJ : 145.26 (-0.12%)
ABBV : 87.61 (+0.75%)
RHHBY : 31.5300 (+0.10%)
Roche's Tecentriq Combination Gets Priority Review by FDA

The FDA accepts and grants Priority Review to Roche's (RHHBY) sBLA for Tecentriq in combination with carboplatin and etoposide for the initial treatment of patients withextensive-stage small cell lung...

NVS : 86.90 (-0.21%)
RHHBY : 31.5300 (+0.10%)
AMGN : 194.09 (+1.38%)
BMY : 52.58 (-0.94%)
Genentech's Kadcyla Cut the Risk of Disease Recurring by Half Compared to Herceptin in People With HER2-Positive Early Breast Cancer With Residual Disease After Neoadjuvant Treatment

--- People who have residual disease after neoadjuvant treatment have a worse prognosis than those with no detectable disease -

RHHBY : 31.5300 (+0.10%)
FDA Grants Priority Review to Genentech's Tecentriq in Combination with Chemotherapy for the Initial Treatment of Extensive-Stage Small Cell Lung Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License...

RHHBY : 31.5300 (+0.10%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade RHHBY with:

Key Turning Points

2nd Resistance Point 32.0167
1st Resistance Point 31.7733
Last Price 31.5300
1st Support Level 31.2233
2nd Support Level 30.9167

See More

52-Week High 32.5800
Last Price 31.5300
Fibonacci 61.8% 30.1810
Fibonacci 50% 29.4400
Fibonacci 38.2% 28.6990
52-Week Low 26.3000

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar